Liu Na, Ma Qinying, Zhou Moqing, Yang Lin, Wang Wenyuan, Wang Yanyong
Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Front Neurol. 2025 May 7;16:1554841. doi: 10.3389/fneur.2025.1554841. eCollection 2025.
To investigate the efficacy and mechanisms of stellate ganglion block (SGB) in treating generalized anxiety disorder (GAD) with sleep disturbance, excluding patients with comorbid depression.
This double-blind randomized controlled trial (RCT) enrolled 128 patients with GAD (Hamilton Anxiety Scale [HAMA] > 14, Generalized Anxiety Disorder 7-item Scale [GAD-7] ≥ 5) and sleep disturbance (Pittsburgh Sleep Quality Index [PSQI] ≥ 15), randomized to receive SGB ( = 64, 4 ultrasound-guided 1% lidocaine injections) or conventional treatment ( = 64, cognitive behavioral therapy [CBT] + estazolam 1-2 mg/day). Outcomes included anxiety (HAMA), depression (Hamilton Depression Scale [HAMD]), sleep quality (PSQI), polysomnography (PSG), and neurotransmitter levels (norepinephrine [NE], serotonin [5-HT], neuropeptide Y [NPY]).
After 4 weeks, SGB demonstrated higher efficacy (98.4% vs. 89.1%, = 0.028) and greater reductions in HAMA (9.36 ± 2.34 vs. 11.87 ± 2.71, < 0.001) and HAMD scores (6.87 ± 2.01 vs. 8.09 ± 2.04, < 0.001). PSQI improved significantly in the SGB group (5.74 ± 1.64 vs. 8.03 ± 1.86, < 0.001), with increased total sleep time (TST) (429.76 ± 33.22 vs. 391.13 ± 30.76 min, < 0.001) and efficiency (90.23 ± 13.29% vs. 86.34 ± 12.84%, < 0.001). Neurotransmitter analysis showed reduced NE (289.43 ± 51.68 vs. 253.78 ± 57.12 pg./mL, < 0.05) and increased 5-HT (138.56 ± 19.73 vs. 124.93 ± 18.44 ng/mL, < 0.05) and NPY (453.21 ± 73.41 vs. 402.34 ± 68.12 pg./mL, < 0.05). Adverse events were comparable (6.25% vs. 3.13%, = 0.403).
SGB effectively improves GAD symptoms and sleep quality in patients without comorbid depression, potentially via modulation of NE, 5-HT, and NPY pathways. The exclusion of psychiatric comorbidities enhances the specificity of these findings.
探讨星状神经节阻滞(SGB)治疗伴有睡眠障碍的广泛性焦虑症(GAD)的疗效及机制,排除合并抑郁症的患者。
这项双盲随机对照试验(RCT)纳入了128例GAD患者(汉密尔顿焦虑量表[HAMA]>14,广泛性焦虑症7项量表[GAD-7]≥5)且伴有睡眠障碍(匹兹堡睡眠质量指数[PSQI]≥15),随机分为接受SGB组(n = 64,4次超声引导下注射1%利多卡因)或传统治疗组(n = 64,认知行为疗法[CBT]+艾司唑仑1 - 2mg/天)。观察指标包括焦虑(HAMA)、抑郁(汉密尔顿抑郁量表[HAMD])、睡眠质量(PSQI)、多导睡眠图(PSG)以及神经递质水平(去甲肾上腺素[NE]、血清素[5-HT]、神经肽Y[NPY])。
4周后,SGB显示出更高的疗效(98.4%对89.1%,P = 0.028),HAMA评分(9.36±2.34对11.87±2.71,P<0.001)和HAMD评分(6.87±2.01对8.09±2.04,P<0.001)降低更明显。SGB组PSQI显著改善(5.74±1.64对8.03±1.86,P<0.001),总睡眠时间(TST)增加((429.76±33.22对391.13±30.76分钟,P<0.001),睡眠效率提高(90.23±13.29%对86.34±12.84%,P<0.001)。神经递质分析显示NE降低(289.43±51.68对253.78±57.12pg./mL,P<0.05),5-HT增加(138.56±19.73对124.93±18.44ng/mL,P<0.05),NPY增加(453.21±73.41对402.34±68.12pg./mL,P<0.05)。不良事件发生率相当(6.25%对3.13%,P = 0.403)。
SGB可有效改善无合并抑郁症患者的GAD症状和睡眠质量,可能是通过调节NE、5-HT和NPY通路实现。排除精神共病增强了这些研究结果的特异性。